NANO Share Price Performance
€22.40
18.00 (409.09%)
Price €22.40
Share Price€22.40
Nanobiotix S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
NANO Community Narratives
There are no narratives available yet.
Recent NANO News & Updates
Nanobiotix S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.07
- Gross Margin
- 100.00%
- Net Profit Margin
- -508.35%
- Debt/Equity Ratio
- -69.0%
Nanobiotix S.A. Competitors
Snowflake Analysis
About NANO
- Founded
- 2003
- Employees
- 103
- CEO
- WebsiteView website
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
French Market Performance
- 7 Days: -2.2%
- 3 Months: 0.6%
- 1 Year: 2.8%
- Year to Date: 5.1%
Over the last 7 days, the market has dropped 2.2%, driven by a loss of 3.0% in the Consumer Discretionary sector. Overall the market has been flat in the last year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›